The peptide caused skin irritation but otherwise appeared to be safe
Your provider will decide how long you should continue treatment
With proper documentation and coding, you ensure she gets appropriate cardiac follow-up, her fall risk is addressed, her medications are reviewed, and your facility is properly reimbursed for the complexity of care provided
Some local governments offer mail-back programs for sharps waste
But heres the thingjust because its common doesnt mean its for everyone
not primarily appetite-driven (OUP Academic) Expected weight loss (this is where many people get misled) In major obesity trials: Semaglutide 2.4 mg weekly: ~14.9% mean weight loss at 68 weeks (STEP-1) (PubMed) Tirzepatide: ~15.0% to ~20.9% mean weight loss at 72 weeks , dose-dependent (SURMOUNT-1) (PubMed) AOD-9604s best-known human signal is kilograms, not double-digit percentages , and later studies did not sustain a strong obesity-drug profile